Stay updated on Pembrolizumab Combo in Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Ovarian Cancer Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Ovarian Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedAdded revision note for v3.4.3 and removed the previous v3.4.2 revision.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check32 days agoChange DetectedFallopian tube cancer was added to the Conditions section. A new page revision tag shows Revision: v3.4.2 (replacing v3.4.1).SummaryDifference0.1%

- Check40 days agoChange DetectedThe page now lists Primary Peritoneal Carcinoma and adds a resource link to the Genetic and Rare Diseases Information Center. The site revision updated from v3.4.0 to v3.4.1.SummaryDifference0.2%

- Check47 days agoChange DetectedGlossary toggle text added; metadata labels updated (Last Update Submitted that Met QC Criteria, No FEAR Act data) and Revision: v3.4.0, replacing the previous lowercase variants and Revision: v3.3.4.SummaryDifference0.2%

- Check54 days agoChange DetectedThe Study Record Dates section changes from 'Last Update Posted (Estimated)' to 'Last Update Posted'. This update is limited to a labeling change and does not modify any study data or core content.SummaryDifference0.1%

- Check61 days agoChange DetectedFooter now shows Revision: v3.3.4, replacing Revision: v3.3.3, which is an internal revision update and does not affect study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab Combo in Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Ovarian Cancer Clinical Trial page.